Use of Respiratory Syncytial Virus Vaccines in Older Adults: Recommendations of the Advisory Committee on Immunization Practices — United States, 2023

Michael Melgar, MD 1 ; Amadea Britton, MD 1 ; Lauren E. Roper, MPH 1 ; H. Keipp Talbot, MD 2 ; Sarah S. Long, MD 3 ; Camille N. Kotton, MD 4 ; Fiona P. Havers, MD 1 ( View author affiliations )

View suggested citation Summary

What is already known about this topic? Respiratory syncytial virus (RSV) causes substantial morbidity and mortality in older adults. In May 2023, the Food and Drug Administration approved the first two vaccines for prevention of RSV lower respiratory tract disease (LRTD) for use in adults aged ≥60 years. What is […]

Click here to visit source. www.cdc.gov